SHE:000538

2 stories mentioning SHE:000538Updated 21d ago

Every FINWIRES story that references SHE:000538, newest first.

Yunnan Baiyao Secures US FDA Approval for Metabolic Disorder Drug

Yunnan Baiyao's (SHE:000538) INB301 Injection obtained clearance from the U.S. Food and Drug Administration to conduct clinical trials for treating cancer cachexia.Cancer cachexia is a complex metabolic disorder characterized by persistent muscle wasting, according to a Thursday filing with the Shenzhen bourse.Shares of the drug manufacturer closed 1% lower Thursday.

SHE:000538

Asia56d ago

Yunnan Baiyao's Attributable Profit Jumps 5% in Q1

Yunnan Baiyao's (SHE:000538) attributable profit rose 5.3% to 2.04 billion yuan in the first quarter from 1.93 billion yuan in the year-ago period, according to a Thursday filing with the Shenzhen bourse.Earnings per share at the medical products manufacturer increased 5.6% to 1.14 yuan from 1.08 yuan in the prior-year period.Operating revenue grew 7% year over year to 11.6 billion yuan from 10.8 billion yuan.

SHE:000538

Track with the FINWIRES app suite

FolioX

Track SHE:000538 in your portfolio

WheelAI

Analyze SHE:000538 options with the wheel strategy

StockInsider

See market sentiment on SHE:000538